Arrowhead Pharmaceuticals (ARWR) Appoints Victoria Vakiener to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 2, 2022 7:31 AM EDTPASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022.
Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead said, Vicki is a senior executive with an impressive track record of leading organizations to successfully commercialize important medicines.
Ive watched Arrowhead aggressively grow its pipeline and expand the reach of its RNAi technology over the years, said Ms. Vakiener.... More
